Heart Valve, Spine Markets To Drive Device Growth After DES – CMS Report
This article was originally published in The Gray Sheet
Percutaneous heart valve repair and replacement likely will drive the next wave of medical device industry expansion as cardiac resynchronization therapy (CRT) and drug-eluting stent innovations plateau, a CMS report speculates
You may also be interested in...
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.